This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic rhinitis who are otherwise healthy. The anticipated time on study treatment is 2 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
Unnamed facility
South Miami, Florida, United States
Unnamed facility
Normal, Illinois, United States
Unnamed facility
Raleigh, North Carolina, United States
Unnamed facility
Spartanburg, South Carolina, United States
Assessment of the safety and tolerability of RO4989991
Time frame: 24 weeks
Assessment of pharmacokinetics
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.